A meta-analysis of platinum-based neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy for triple-negative breast cancer

Future Oncol. 2019 Aug;15(23):2779-2790. doi: 10.2217/fon-2019-0165. Epub 2019 Jul 11.

Abstract

Aim: Platinum agents are DNA damaging agents with promising activity in breast cancers, especially in triple-negative subgroup. This meta-analysis was conducted to compare the treatments of platinum-based neoadjuvant chemotherapy (NAC) and standard NAC for triple-negative breast cancers (TNBCs). Materials & methods: Diverse electronic databases were searched to identify the randomized clinical trials that directly compared the treatments of platinum-based NAC versus NAC in TNBC patients. Toxicity of platinum-based regimens was further evaluated. Results: Addition of platinum agents significantly improved the pathological complete response rates in TNBC patients compared with the standard NAC. Unfortunately, platinum-based regimens were more likely to develop higher incidence of hematologic toxicities. Conclusion: Platinum-based NAC regimens could achieve significant pathological complete response improvement with well-tolerated toxicity in TNBC patients.

Keywords: meta-analysis; neoadjuvant chemotherapy; pathological complete response; platinum agents; triple-negative breast cancer.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Carboplatin / adverse effects
  • Carboplatin / therapeutic use
  • Cisplatin / adverse effects
  • Cisplatin / therapeutic use
  • Female
  • Humans
  • Neoadjuvant Therapy / methods*
  • Platinum Compounds / adverse effects
  • Platinum Compounds / therapeutic use*
  • Receptor, ErbB-2 / metabolism
  • Receptors, Estrogen / metabolism
  • Receptors, Progesterone / metabolism
  • Triple Negative Breast Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents
  • Platinum Compounds
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Carboplatin
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Cisplatin